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A B S T R A C TObjective: Nonsevere hypoglycemic events are common and may
occur in one-third of persons with diabetes as often as several times
a week. This study’s objective was to examine the economic burden of
nonsevere nocturnal hypoglycemic events (NSNHEs). Methods: A 20-
minute Web-based survey, with items derived from the literature,
expert input, and patient interviews, assessing the impact of NSNHEs
was administered in nine countries to 18 years and older patients
with self-reported diabetes having an NSNHE in the past month.
Results: A total of 20,212 persons were screened, with 2,108 respond-
ents meeting criteria and included in the analysis sample. The cost of
lost work productivity per NSNHE was estimated to be between $10.21
(Germany) and $28.13 (the United Kingdom), representing 3.3 to 7.5
hours of lost work time per event. A reduction in work productivity
(presenteeism) was also reported. Compared with respondents’ usual
blood sugar monitoring practice, on average, 3.6  6.6 extra tests weresee front matter Copyright & 2013, International S
r Inc.
1016/j.jval.2013.09.002
hebrodgroup.net.
ondence to: Meryl Brod, The Brod Group, 219 Juliaconducted in the week following the event at a cost of approximately
$87.1 per year. Additional costs were also incurred for doctor visits as
well as medical care required because of falls or injuries incurred
during the NSNHE for an annual cost of $2,111.3 per person per year.
When taking into consideration the multiple impacts of NSNHEs for
the total sample and the frequency that these events occur, the
resulting total annual economic burden was $288,000 or $127 per
person per event. Conclusions: NSNHEs have serious consequences
for patients. Greater attention to treatments that reduce NSNHEs can
have a major impact on reducing the economic burden of diabetes.
Keywords: economic burden, nocturnal hypoglycemia, resource
utilization, work productivity.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Nonsevere hypoglycemic events are common in both type 1 and
type 2 diabetes and may occur in approximately one-third of
persons with diabetes, with frequency of events as often as
several times a week [1]. These events can occur at any time of
day or night while patients are at rest or engaged in activities [1–
3]. These events represent a major challenge for both patients
and clinicians, interfere with optimal long-term diabetes control,
and contribute to excess morbidity and mortality [4–6]. In addi-
tion, nonsevere hypoglycemia has been shown to have an
economic burden for patients, employers and health care payer
systems [7], increased blood glucose (BG) monitoring, health care
resource utilization, and patient out-of-pocket expenses [7,8].
In previous survey studies of both nighttime and daytime
events, nonsevere nocturnal hypoglycemic events (NSNHEs),
those occurring while sleeping, have been shown to potentially
have a greater impact than daytime events on lost work produc-
tivity due to both absenteeism and presenteeism [7]. Further-
more, qualitative research has shown that nighttime events
disrupt both sleep quality and quantity, resulting in impaired
functioning and well-being the following day [8]. Thus, previous
quantitative as well as qualitative research on NSNHEs has begunto suggest that these events are consequential contributors to
increasing health care costs as well as the overall economic
burden of diabetes [3,7,8]. The purpose of this study was to
explore, in greater depth than has previously been done, the
economic burden of these NSNHEs in terms of lost work produc-
tivity and health care resource utilization. This information is
critical data that can be instrumental in helping to better under-
stand, manage, and contain costs associated with these events
and reduce the overall cost of care.Methods
Survey Development and Conduct
A survey assessing the impact of NSNHEs was developed on the
basis of the literature, expert input, and interviews with 78
persons with diabetes in nine focus groups in four countries
(the United States, the United Kingdom, Germany, and France)
who recently had experienced an NSNHE [8]. The survey items
were developed on the basis of a qualitative analysis of the expert
input and the persons with diabetes interviews and cognitively
debriefed and pilot tested in English in nine persons who met theociety for Pharmacoeconomics and Outcomes Research (ISPOR).
Avenue, Mill Valley, CA 94941, USA.
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conducted to ensure content validity (relevant questions) and to
ensure that the questions had face validity with the respondents
(e.g., no unfamiliar/strange words or concepts). The ﬁnal ques-
tionnaire was translated into all relevant languages by using a
forward and backward translation process [8]. The survey was
administered via a secure Internet server in the United States, the
United Kingdom, Germany, Canada, France, Italy, Spain, The
Netherlands, and Sweden. Findings, based on the current survey
regarding the impact of NSNHEs on daily functioning and
diabetes management, have been previously published [9].
NSNHEs were deﬁned for the respondent as “nighttime hypo-
glycemic episode that happened while you were sleeping and did
not require medical attention (such as needing to call an
ambulance, go to the emergency room/hospital) or did not
require help from anyone else to manage the hypo. You knew
that you were having this hypoglycemic episode because you had
symptoms like sweating and/or confusion or perhaps you expe-
rienced no symptoms, but noted the hypoglycemic episode when
measuring your blood sugar.” Respondents were asked questions
regarding reasons for the event, length of time of the event,
impact on productivity, daily functioning, and well-being. The
survey took approximately 20 minutes to complete, and respond-
ents were remunerated US $3 to US $5 depending on country for
completing the survey. The survey had several real-time valida-
tion steps (e.g., plausible min–max input values) and skip-
patterns depending on the respondents’ reply. Before database
release, additional cross-checks were performed.Sample
To be eligible to complete the survey, the respondent had to have
a self-reported diagnosis of diabetes and experienced at least one
NSNHE in the past month, be 18 years or older, and able to read
the predominant language of the country he or she was living in.
To ensure the generalizability of the results and reduce recruit-
ment source bias, a multisource informant strategy was used. A
multisource informant strategy is important when conducting
correlational/regression-oriented research because it allows one
to examine associations between predictors and outcomes when
common method or source variance is not shared and enables
researchers to rule out alternative explanations that would
probably not be testable with single-source, single-method data
sets [10,11]. The multisource informant strategy included a
preconsented, online patient panel, e-mail recruitment, afﬁliate
networks, and Web site advertising. Patients were recruited from
more than 100 Web sites as well as from face-to-face and
telephone surveys where appropriate to include members who
were not frequent online users. Furthermore, all respondents
were blinded to the purpose of the survey before entering the
survey to reduce the possibility of self-identifying as a person
with diabetes for the purpose of completing the survey. All
respondents had either been identiﬁed as a person with diabetes
and age 18 years or older in a prior blinded survey as a
prerequisite of being a panel member (not related to this study)
or, if not a member of the panel, by answering a blinded question
asking about all their diagnoses and then being invited to enter
the survey only if diabetes was listed as a diagnosis. In addition,
the panel was constituted to be representative of the general
population for age, sex, race, and income, and used for research
only; panelists were not exposed to third-party advertising or
direct marketing campaigns, nor were their personal data sold to
third parties. The panel was also frequently refreshed to ensure
that the panel was dynamic in nature and reﬂected any changes
in the online population that might be occurring. Last, the
incentive was low (US $3–$5 depending on country) to help
ensure that there was no undue incentive to participate in thepanel. The incentive amount was set by the survey administra-
tors on the basis of the length of the survey and historical
knowledge of respondent expectations, and was consistent with
honoraria given for similar surveys. Because of ethical consid-
erations, the same honorarium was given to both panel and
nonpanel respondents. For panel members, the honorarium was
given as a “credit” that could be combined with “credits” from
other surveys and redeemed at a later point in time.
The selection process used a sampling frame in a preexisting
panel of persons with self-reported type 1 or type 2 diabetes. All
respondents went through a health care proﬁler (screening
questions) to ensure that a physician had diagnosed their
diabetes and that a relevant treatment was initiated. A stratiﬁed
sampling procedure used invitation selection criteria to account
for disproportional response rates between stratiﬁcation cate-
gories. Stratiﬁcation variables were age (18–29 years, 30–49 years,
50–64 years, and Z65 years), diabetes type (type 1 diabetes
and type 2 diabetes), sex, and working status (working and
nonworking).
Statistical Testing
Results by country are presented via frequencies or descriptives
(means and SDs) with differences explored by using analysis of
variance for continuous variables and Pearson chi-square for
proportions. Statistical signiﬁcance was tested between countries
with the highest and lowest values. Responses for amount of
work time lost contained outliers (4180 hours), or observations
that appeared to be inconsistent with other observations in the
data set. To account for these departures from normality, a 5%
trim was used [12]. This trim was used for the analysis for
calculating the cost of lost work productivity and resulted in
two cases being dropped. The human capital approach using
average wages to estimate productivity was used. To estimate
input for the human capital method, an average of 36.8 working
hours per week (corresponding to the self-reported working
hours in Table 1) with an estimated 47 working weeks per year
(a total of 1730 working hours per year) was used. The 2011 gross
domestic product per capita was used as an estimate for annual
income [13]. An estimated average income (in US $) of $29.79/h in
the United States, $22.25/h in the United Kingdom, $23.34/h
in Germany, $24.98/h in Canada, $21.64/h in France, $18.78/h in
Italy, $18.84/h in Spain, $25.96/h in The Netherlands, and $24.86/h
in Sweden was used to estimate the value of the lost productivity
[13]. The estimated productivity loss per NSNHE because of
absenteeism was calculated on the basis of the proportion of
persons reporting missed work multiplied with the hourly
income multiplied with the hours missed (e.g., for an NSNHE
during working hours in the United States, 12.6% of the sample
reported missing work for 3.5 hours at the cost of $29.79/h, which
is approximately equal to $13.37 per event).
The costs for doctor visits (or other health care professional)
were derived from in-country data (Spain [14], Italy [15], France
[16], The Netherlands [17], Sweden [18], the United Kingdom [19],
the United States [20], Canada [20], and Germany [21,22]). The
costs were converted into US $ by using the International
Monetary Fund exchange rate data on June 1, 2012 [23]. The costs
per visit used to estimate the value of general practitioner visits
were $40.66 (Spain), $28.34 (Italy), $28.34 (France), $34.50 (The
Netherlands), $164.72 (Sweden), $47.50 (the United Kingdom),
$65.51 (the United States), $65.51 (Canada), and $38.20 (Germany).
Presenteeism was assessed by using the Endicott Work Pro-
ductivity Scale [24] as well as a patient-reported Likert scale
assessment. The Endicott Work Productivity Scale is a 25-item
measure assessing the impact of a disease/event on a person’s
ability to perform work functions due to behaviors and subjective
feelings or attitudes (e.g., ability to concentrate or impatience or
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time frame asked respondents to rate the impact on their work
the day following their last NSNHE. For the 0 to 10 scale rating
“how much this hypo impacted productivity at work,” 0 repre-
sented “My hypo did not impact my productivity at work at all”
and 10 represented “My hypo had an extremely negative impact
on my productivity at work,” mirroring the standard interpreta-
tions of Cohen’s effect size [25] classiﬁcations of mild, moderate,
and severe. Thus, mean scores were collapsed to “no impact
(score 0), “a little impact” (scores 1–2), moderate impact (3–6), and
high impact (scores 7–10).Results
The Sample
A total of 20,212 respondents with self-reported diabetes were
screened. Of these, 2,673 (13.2% prevalence) reported an NSNHE
during the last month and were eligible for the study. Of those
eligible, 2,108 completed the survey for a response rate of 78.9%.
A little over half, 52.2% of the analytic sample (n ¼ 1,100),
reported working for pay. The sample was equally divided
between men and women (49.8%/50.2%), with a mean age of
49.9 years. The mean diabetes duration was 13.7 years, and
subjects reported approximately 2 comorbid conditions on aver-
age (ranging between 0 and 11 out of a possible list of 13 most
common comorbid conditions). As per the stratiﬁed inclusion
criteria, two-third (67.2%) of the sample had type 2 diabetes. The
majority of the sample used insulin (74.2%), with the remainder
on oral treatments only. The majority of the respondents (32.1%)
reported experiencing an NSNHE at least several times a month
(insulin ¼ 33.7%, oral ¼ 27.6%), 15.9% about once a week (insulin
¼ 16.0%, oral ¼ 15.8%), 7.7% not daily but more than once a week
(insulin ¼ 7.1%, oral ¼ 9.6%), and 0.9% daily (insulin ¼ 0.8%, oral ¼
1.1%). The rest of the sample (43.3%) reported having NSNHEs
once a month to very rarely (insulin ¼ 42.5%, oral ¼ 45.9%). No
signiﬁcant differences in experience were found (P ¼ 0.063)
between patients in insulin and oral treatments or those with
and without comorbidity. The overall recall period for when the
event occurred was short, with 76.3% (n ¼ 1609) reporting having
an NSNHE within the last 2 weeks (insulin ¼ 77.1%, oral ¼ 74.2%)
(Table 1).
Impact of NSNHE on Work Productivity
Of working respondents, 13.8% (n ¼ 151) reported missing work
time, of which 2.6% (n ¼ 28) missed a full day and 11.2% (n ¼ 123)
missed partial day (either going late to work the next day or
leaving early) because of the NSNHE. For those missing work, the
average working time lost was 5.3  11.8 hours. Patients on
insulin also had a higher percentage of work absence (66.7%) than
did those on oral treatment (33.3%) (P ¼ 0.076).
Based on Endicott Work Productivity Scale scores, the impact
of the NSNHE on presenteeism had a mean score of 21.3  21.0,
which is signiﬁcantly higher than that for groups deﬁned as
normal controls in two recent studies (ranging from mean 3.54
[26] and mean 15.6  11.7 to 18.2  10.7 [27]), comparable to the
score among patients with arthritis (mean ¼ 21.5  14.3) [28] and
lower than the score among patients reporting psychiatric dis-
orders (mean ¼ 40.8  21.6) [29]. Patients on insulin had a lower
(better) score (mean ¼ 19.2  20.8) than did those on oral
treatment (mean ¼ 27.0  21.0; P o 0.001).
For those who worked the next day, the impact of the
previous night event was apparent, with 42.6% of the respond-
ents reporting that they had trouble focusing or concentrating the
next day at work, 20.1% not completing work tasks on time, and15.6% needing to reschedule their work day. Twenty-ﬁve percent
of the sample reported that the NSNHE had a high impact on
productivity at work the following day, 32.1% reported moderate
impact, 18.9% reported a little impact, and 24.0% reported no
impact of the NSNHE on their work productivity (Table 2).
The total yearly cost of lost work productivity for the working
sample (52% of total sample) due to working either a partial day
or missing a full day of work, based on the number of reported
events per month in the working sample, was estimated to be
$520.4 (insulin ¼ $452.7, oral ¼ $586.0; P ¼ 0.277) per working
person. Costs per country varied signiﬁcantly, ranging from
$216.3 (Germany) to $1,171.5 (Italy) (P o 0.002).
Post hoc regression analyses using productivity at work
questions as dependent variables showed that comorbidity did
not have a signiﬁcant impact on whether respondents “go late to
work because of the hypo” or miss a full day/days of work
because of the hypo. For those with greater comorbidity, how-
ever, NSNHEs did have a signiﬁcantly greater, negative impact at
work on their work productivity (P o 0.001) and resulted in
leaving work early more often (P ¼ 0.01) (Table 3).
Impact on Diabetes Management and Health Care Resource
Utilization
There was an increase in health services utilization reported,
with 14.8% (n ¼ 313) of the respondents contacting a primary care
doctor or clinic as a result of having an NSNHE, with subjects on
orals only having a signiﬁcantly higher contact rate than did
those on insulin (22.3% vs. 12.3%, respectively, P o 0.01). In
addition, of the 1,873 subjects who reported having an NSNHE
that woke them up, 145 respondents (7.7%) tripped or fell as a
result of the NSNHE, of which 31.0% (n ¼ 45) hurt themselves, and
of these 26.7% (n ¼ 12) required a visit to a doctor or other health
professional. Subjects on insulin reported fewer trips/falls than
did subjects on orals only (6.1% vs. 9.2%, Po 0.05); however, there
were no differences in who hurt themselves or who required a
visit to a doctor.
Compared with respondents’ usual blood sugar monitoring
practice, on average, 3.6  6.6 extra tests were conducted in the
week following the event, with no signiﬁcant difference between
those taking insulin (3.5  6.8) and orals (3.9  5.8). The estimated
yearly health care utilization cost due to NSNHEs for increased BG
monitoring was $87.1  313.9, assuming $1 cost per BG monitor-
ing strip. The estimated yearly cost for visits to health care
providers for falls and trips resulting in injury was $2,111.3 per
person who experienced a fall. The costs varied between coun-
tries, ranging from between $786 in the United States to the
highest $10,203 in Italy. No test for signiﬁcance was made
because the variance between countries was too high (Table 4).
Total Economic Burden
When taking into consideration the multiple impacts of NSNHEs
(lost work time assuming that 52% of the sample is working,
increased diabetes management, and increased health service
resource utilization) and the frequency that these events occur,
the resulting total annual economic burden for this sample was
$288,000 or $127 per person per event. The amounts by country,
from lowest to highest, were $8,700 (Sweden), $13,335 (The
Netherlands), $18,268 (Canada), $27,274 (Germany), $34,536 (the
United Kingdom), $39,083 (Italy), $41,108 (France), $44,724 (the
United States), and $46,620 (Spain).Discussion
This study has conﬁrmed that NSNHEs are not uncommon in
patients with type 1 and type 2 and occur in the past month in
Table 1 – Sample demographic characteristics.
Total UK Germany USA Canada France Italy Spain The
Netherlands
Sweden P
Sample size with NSNHE
within last month (N)
2108 305 279 501 200 193 138 242 169 81
Age (y), mean  SD (range) 49.9  13.6
(20–89)
48.4  13.4
(20–81)
49.0  13.6
(20–85)
53.7  13.0
(20–89)
54.5  12.6
(22–83)
45.9  13.5
(20–83)
44.6  12.5
(20–76)
42.2  11.9
(20–77)
55.3  11.2
(22–81)
54.7  13.5
(23–81)
0.000*
Sex: female, n (%) 1059 (50.2) 153 (50.2) 123 (44.1) 300 (59.9) 120 (60.0) 89 (46.1) 56 (40.6) 105 (43.4) 76 (45.0) 37 (45.7) 0.000†
Type of diabetes, n (%) 0.000†
Type 1 692 (32.8) 109 (35.7) 88 (31.5) 122 (24.4) 50 (25.0) 83 (43.0) 75 (54.3) 75 (31.0) 44 (26.0) 46 (56.8)
Type 2 1416 (67.2) 196 (64.3) 191 (68.5) 379 (75.6) 150 (75.0) 110 (57.0) 63 (45.7) 167 (69.0) 125 (74.0) 35 (43.2)
Diabetes duration (y), mean 
SD (range)
13.7  11.3
(0.1–75.6)
13.6  11.8
(0.4–57)
11.8  9.7
(0.1–49)
14.8  11.8
(0.3–60.7)
14.4  10.7
(0.3–48)
13.7  11.0
(0.3–50.3)
14.2  12.3
(0.1–75.6)
10.2  8.5
(0.3–49.6)
14.0  11.3
(1.4–70.3)
21.4  14.3
(1.6–58.3)
0.000*
Number of medical
complications, mean  SD
(range)
1.1  1.2
(0–6)
1.0  1.2
(0–6)
1.0  1.0
(0–5)
1.4  1.3
(0–6)
1.2  1.2
(0–5)
0.9  1.1
(0–5)
0.9  1.0
(0–4)
0.9  1.0
(0–5)
1.0 1.0
(0–4)
1.0  1.3
(0–5)
0.000*
Diabetes treatment, n (%) 0.000†
Insulin 1565 (74.2) 210 (68.9) 226 (81.0) 351 (70.1) 139 (69.5) 156 (80.8) 106 (76.8) 164 (67.8) 135 (79.9) 78 (96.3)
Orals 543 (25.7) 95 (31.1) 53 (19.0) 150 (29.9) 61 (30.5) 37 (19.2) 32 (23.2) 78 (32.2) 34 (20.1) 3 (3.7)
Work for pay, n (%) 0.000†
Yes 1100 (52.2) 156 (51.1) 166 (59.5) 208 (41.5) 87 (43.5) 108 (56.0) 91 (65.9) 169 (69.8) 76 (45.0) 39 (48.1)
No 1008 (47.8) 149 (48.9) 113 (40.5) 293 (58.5) 113 (56.5) 85 (44.0) 47 (34.1) 73 (30.2) 93 (55.0) 42 (51.9)
Hours worked per week, mean
 SD
36.8  11.0 33.7  11.7 38.6  11.6 36.5  11.3 35.7  10.7 38.2  9.0 37.0  9.2 40.2  8.8 32.3  13.2 35.3  11.2 0.000*
Frequency of NSNHE,‡
n (%)
All (type 1 and type 2)
(N ¼ 2108)
0.000†
Daily 18 (0.9) 1 (0.3) 3 (1.1) 4 (0.8) 1 (0.5) 4 (2.1) 2 (1.4) 3 (1.2) 0 (0.0) 0 (0.0)
Not daily, but more than
once a week
163 (7.7) 15 (4.9) 13 (4.7) 59 (11.8) 14 (7.0) 20 (10.4) 11 (8.0) 19 (7.9) 10 (5.9) 2 (2.5)
About once a week 336 (15.9) 61 (20.0) 48 (17.2) 72 (14.4) 17 (8.5) 35 (18.1) 23 (16.7) 37 (15.3) 28 (16.6) 15 (18.5)
Several times a month 677 (32.1) 88 (28.9) 88 (31.5) 164 (32.7) 70 (35.0) 71 (36.8) 48 (34.8) 82 (33.9) 50 (29.6) 16 (19.8)
Once a month 414 (19.6) 59 (19.3) 69 (24.7) 85 (17.0) 28 (14.0) 32 (16.6) 28 (20.3) 43 (17.8) 41 (24.3) 29 (35.8)
Only a few times a year 401 (19.0) 68 (22.2) 49 (17.6) 83 (16.6) 58 (29.0) 25 (13.0) 23 (16.7) 47 (19.4) 36 (21.3) 12 (14.8)
Very rarely 99 (4.7) 13 (4.3) 9 (3.2) 34 (6.8) 12 (6.0) 6 (3.1) 3 (2.2) 11 (4.5) 4 (2.4) 7 (8.6)
Type 1 (n ¼ 692) 0.002†
Daily 8 (1.2) 0 (0.0) 3 (3.4) 0 (0.0) 0 (0.0) 2 (2.4) 2 (2.7) 1 (1.3) 0 (0.0) 0 (0.0)
Not daily, but more than
once a week
52 (7.5) 5 (4.6) 0 (0.0) 20 (16.4) 2 (4.0) 6 (7.2) 8 (10.7) 5 (6.7) 4 (9.1) 2 (4.3)
About once a week 134 (19.3) 27 (24.8) 18 (20.5) 22 (18.0) 5 (10.0) 18 (21.7) 14 (18.7) 9 (12.0) 9 (20.5) 12 (26.0)
Several times a month 232 (33.5) 32 (29.4) 26 (29.5) 42 (34.4) 22 (44.0) 33 (39.8) 24 (32.0) 30 (40.0) 14 (31.8) 9 (19.6)
Once a month 141 (20.4) 19 (17.4) 24 (27.3) 18 (14.8) 11 (22.0) 14 (16.9) 13 (17.3) 11 (14.7) 12 (27.3) 19 (41.3)
Only a few times a year 115 (16.6) 23 (21.1) 17 (19.3) 17 (13.9) 10 (20.0) 9 (10.8) 12 (16.0) 18 (24.0) 5 (11.4) 4 (8.7)
Very rarely 10 (1.4) 3 (2.8) 0 (0.0) 3 (2.5) 0 (0.0) 1 (1.2) 2 (2.7) 1 (1.3) 0 (0.0) 0 (0.0)
Type 2 (n ¼ 1416) 0.003†
Daily 10 (0.7) 1 (0.5) 0 (0.0) 4 (1.1) 1 (0.7) 2 (1.8) 0 (0.0) 2 (1.2) 0 (0.0) 0 (0.0)
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similar regardless of diabetes type (450% at least monthly).
Furthermore, although the incidence of hypoglycemic events
may be lower for patients on orals than on insulin [30], random-
ized controlled trial studies have shown that rates may be as high
as 38% for patients on oral treatments [31]. As shown in this
study, however, for those patients who do have NSNHEs, the
frequency of these events is similar to that of patients on insulin.
There was also no difference in the frequency of events for those
with less comorbidity. Patients on orals, however, as well as
those with a fewer number of comorbidities, did report a lower
impact on work productivity and less work absenteeism due to
NSNHEs. This suggests that for this subset of patients, the
consequences of the event may be less for those with less
comorbidity or on oral treatment only. This evidence should
further dispel the myth that nonsevere events are a concern only
to patients with type 1 diabetes.
The longer term impacts of these events such as poor con-
centration last far longer than the immediate experience of the
acute symptoms of the NSNHE (shaking, sweats, etc.) and can
impact next-day functioning at work as well as daily functioning
and well-being. Clearly, these events are “non-minor” or “non-
severe,” and labeling these events as such is a serious misnomer
and may contribute to the lack of attention or appreciation of the
importance of NSNHEs by a portion of clinicians. We suggest that
calling these events “self-treated hypoglycemia” would be more
accurate as well as less dismissive of their consequences.
The total economic burden of NSNHEs must include not only
lost work productivity but also costs incurred for increased
diabetes management and health care resource utilization. Using
a human capital approach, the lost productivity per NSNHE was
estimated in the range from $10.21 to $28.13 across all nine
countries. The extrapolated yearly costs for these events are in
the range of $216.3 to $1,171.5 per patient. With regard to
increased diabetes management costs, however, the number of
extra BG tests per NSNHE was estimated in the range from 1.8 to
6.8 across all countries, with an average yearly cost of $87.1 per
person. In addition, increased health care utilization accounted
for $2,111 per person in yearly costs due to falls resulting from
the NSNHE. It should be noted, however, that only less than 1% of
the population experienced falls and further research is needed
to understand these costs in a larger sample. The total yearly cost
for all reasons as a result of NSNHEs is estimated to be $288,000
for this sample. Furthermore, these costs may be an under-
estimation for three reasons. First, the full extent of the economic
burden of these NSNHEs on work productivity does not include
the impact of the NSNHE on the ability to be productive at work
(presenteeism) and the cost of reduced focus or concentration at
work. Second, the increased health care resource utilization costs
due to additional contacts with health care providers (additional
phone calls or questions to health care providers reported in this
survey by 14.8% of the respondents) could not be estimated
because of lack of information on parameters (e.g., length) of
the contact. In addition, because it was not known whether those
who missed work because of an event were hourly or salaried
workers, this may have impacted their ability or willingness to
miss work time because of the event. Last, the total economic
burden as a result of the NSNHE should also include the addi-
tional out-of-pocket costs of the individual patient to manage
these events. This was not assessed in this study although
previous studies have found these costs to be consequential;
the average dollar amount spent per year per person to manage
nonsevere hypoglycemic events was $25/month for purchases
such as increased number of glucose monitoring strips or food
purchases more substantial than just a sugar packet or juice [7].
It is of note that the impact of NSNHEs on work productivity
(presenteeism) is similar to that of arthritis, a major debilitating
Table 2 – Impact of an NSNHE on work productivity.
Total UK Germany USA Canada France Italy Spain The Netherlands Sweden P
NSNHE, Working for pay N (with 5% trim)* N ¼ 1098 N ¼ 155 N ¼ 166 N ¼ 207 N ¼ 87 N ¼ 108 N ¼ 91 N ¼ 169 N ¼ 76 N ¼ 39
How much did hypo impact productivity
at work (0 ¼ no impact; 10 ¼ extremely
negative impact), mean  SD
3.8  3.1 4.5  3.1 3.6  3.1 3.4  3.1 4.4  3.2 3.9  3.0 3.2  2.9 3.8  2.9 3.7  3.0 2.5  3.0 0.001†
Missing work time (late to work/leave
early/miss full day), n (%)
151 (13.8) 26 (16.8) 22 (13.3) 26 (12.6) 15 (17.2) 16 (14.8) 11 (12.1) 20 (11.8) 7 (9.2) 8 (20.5) 0.663‡
If missing work time, what was the
amount of work time lost (late to
work/leave early/miss full day) (h),
mean  SD
5.3  11.8 7.5  15.7 3.3  5.5 3.5  10.8 3.5  3.3 3.9  8.7 5.7  6.5 10.4  20.7 5.6  7.4 2.2  2.5 0.538†
Because of the hypo, did you: n (%)
Postpone work appointments 68 (6.2) 11 (7.1) 13 (7.8) 12 (5.8) 9 (10.3) 7 (6.5) 4 (4.4) 7 (4.1) 2 (2.6) 3 (7.7) 0.518‡
Reschedule work day 171 (15.6) 21 (13.5) 30 (18.1) 20 (9.7) 16 (18.4) 20 (18.5) 11 (12.1) 35 (20.7) 12 (15.8) 6 (15.4) 0.141‡
Have difﬁculty focusing or concentrating
at work
468 (42.6) 81 (52.3) 86 (51.8) 83 (40.1) 39 (44.8) 41 (38.0) 34 (37.4) 62 (36.7) 30 (39.5) 12 (30.8) 0.013‡
Not complete work tasks and/or activities
in a timely manner
221 (20.1) 41 (26.5) 26 (15.7) 47 (22.7) 21 (24.1) 17 (15.7) 8 (8.8) 40 (23.7) 13 (17.1) 8 (20.5) 0.022‡
Feel people at work noticed you were
experiencing effects of the hypo from
the night before
167 (15.2) 33 (21.3) 18 (10.8) 34 (16.4) 13 (14.9) 17 (15.7) 11 (12.1) 29 (17.2) 5 (6.6) 7 (17.9) 0.113‡
NSNHE, nonsevere nocturnal hypoglycemic event.
 The top 5% was trimmed for these results. This dropped two subjects (one from the USA and one from the UK).
† Analysis of variance.
‡ Chi-square.
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Table 3 – The economic cost of lost work productivity due to NSNHEs.
Total UK Germany USA Canada France Italy Spain The
Netherlands
Sweden
NSNHE, Working for pay N (with 5% trim)* N ¼ 1098 N ¼ 155 N ¼ 166 N ¼ 207 N ¼ 87 N ¼ 108 N ¼ 91 N ¼ 169 N ¼ 76 N ¼ 39
Work absenteeism
Data regarding the last NSNHE
Missing work time (late work/leave early/miss
full day), n (%)
151 (13.8) 26 (16.8) 22 (13.3) 26 (12.6) 15 (17.2) 16 (14.8) 11 (12.1) 20 (11.8) 7 (9.2) 8 (20.5)
Hourly income (US $) 23.38 22.25 23.34 29.79 24.98 21.64 18.78 18.84 25.96 24.86
The amount of work time lost (late work/leave
early/miss full day) (h), mean  SD
5.3  11.8 7.5  15.7 3.3  5.5 3.5  10.8 3.5  3.3 3.9  8.7 5.7  6.5 10.4  20.7 5.6  7.4 2.2  2.5
Cost of productivity loss per event (US $) 17.14 28.13 10.21 13.37 14.89 12.60 12.98 23.14 13.38 11.12
Lost work productivity (for subsample who
reported missing work time)
Estimated yearly lost productivity per person
Event frequency of NSNHEs per year, mean† 30 20.4 21.6 36 20.4 31.2 91.2 21.6 16.8 21.6
Productivity loss of an NSNHE (US $)‡ 520.4 578.7 216.3 488.0 303.2 395.0 1171.5 507.9 219.8 248.1
NSNHE, nonsevere nocturnal hypoglycemic event.
 The top 5% was trimmed for these results. This dropped two subjects (one from the USA and one from the UK).
† Mean calculated for subjects who indicated “missing work time”; the mean estimated yearly events was based on their reported frequency of events where daily ¼ 360, not daily but more
than once per week ¼ 104, about once a week ¼ 52, several times a month ¼ 24, and once a month ¼ 12.
‡ Calculated by multiplying the number of events by the cost of productivity loss per cost.
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Table 4 – Medical resource utilization after the last NSNHE.
Total
(N ¼ 2108)
UK
(N ¼ 305)
Germany
(N ¼ 279)
USA
(N ¼ 501)
Canada
(N ¼ 200)
France
(N ¼ 193)
Italy
(N ¼ 138)
Spain
(N ¼ 242)
The
Netherlands
(N ¼ 169)
Sweden
(N ¼ 81)
P
Number of extra blood sugar tests
after the last NSNHE, mean  SD
1st day (day of the NSNHE) 1.3  1.5 1.3  1.4 1.3  1.3 1.1  1.3 1.4  1.6 1.1  1.4 1.4  1.2 1.8  1.9 1.3  1.4 1.0  1.2 0.000*
2nd day 0.6  1.2 0.6  1.1 0.5  1.0 0.4  0.9 0.8  1.4 0.6  1.1 0.9  1.1 1.1  1.6 0.5  1.1 0.2  0.7 0.000*
3rd day 0.4  1.0 0.4  1.0 0.3  0.9 0.3  0.8 0.5  1.2 0.5  1.0 0.6  1.0 0.9  1.6 0.3  0.9 0.1  0.7 0.000*
4–7 d 1.3  3.6 1.1  3.3 0.8  2.9 0.8  2.7 1.4  4.0 1.5  3.9 1.6  3.3 3.0  5.5 0.9  2.6 0.5  2.4 0.000*
Total (7 d after the NSNHE) 3.6  6.6 3.4  6.1 3.0  5.5 2.5  5.0 4.2  7.5 3.8  6.8 4.5  6.1 6.8  10.0 3.0  5.3 1.8  4.2 0.000*
Contacted a health care professional
after the last NSNHE, n (%)
Yes† 313 (14.8) 36 (11.8) 61 (21.9) 40 (8.0) 29 (14.5) 33 (17.1) 35 (25.4) 58 (24.0) 16 (9.5) 5 (6.2) 0.000‡
Falls and trips
Did you trip and/or fall during this
nighttime hypo? Yes, n (%)§
145 (7.7) 25 (9.4) 23 (9.9) 27 (6.2) 6 (3.4) 21 (12.1) 8 (6.2) 25 (11.5) 5 (3.1%) 5 (6.5%) 0.003‡
When you trip/fall, did you hurt
yourself? Yes, n (%)
45 (31.0) 12 (48.0) 1 (4.3) 7 (25.9) 0 (0.0%) 7 (33.3) 2 (25.0) 12 (48.0) 3 (60.0) 1 (20.0) 0.011‡
Did this trip/fall require a
visit to doctor or other
health professional? Yes,
n (%)
12 (26.7) 4 (33.3) 0 (0.0) 1 (14.3) – 1 (14.3) 1 (50.0) 4 (33.0) 0 (0.0) 1 (100) 0.493‡
Estimated yearly cost for falls per
person (US $)
2,111.3 1,282.4 – 786.1 – 1,360.3 10,202.6 975.9 – 3,253.3 –
NSNHE, nonsevere nocturnal hypoglycemic event.
 Analysis of variance.
† Primary care doctor, hospital, diabetes clinic, other.
‡ Chi-square.
§ Data on falls were calculated on the subjects who reported having an NSNHE that woke them up (n ¼ 1873).
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V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 1 1 4 0 – 1 1 4 91148disease with a major impact on patient functioning and well-
being as well as economic costs of care [32–35]. In addition, the
estimated yearly economic burden of these events is slightly less
than the yearly economic burden of inﬂuenza (372 million) in the
United States [36].
This survey also identiﬁed a previously undiscussed economic
impact of NSNHEs, namely, falls or injuries due to the event. Falls
and subsequent visits to health care providers are both fright-
ening to patients and represent an additional health care cost.
Given that the elderly are more prone to falls [37], that the
prevalence of diabetes increases with age [38], and that there is a
47% increased risk of recurrent falls in this cohort [39], one can
assume that the economic burden for this population is even
greater than for younger persons with diabetes. In addition, it
was unknown whether these respondents also had orthostatic
hypotension, which may have contributed as a risk factor for
falling. Further research is needed to better understand the
prevalence and economic implications for these falls and injuries
as a consequence of NSNHEs.
As expected, country differences were found. The samples in
The Netherlands and Germany seem to have a lower economic
burden (in terms of cost) than the samples in other countries.
Respondents from the United Kingdom and Spain reported
higher global costs, while Italy had the highest per person costs
dealing with their NSNHEs. The higher costs for Italy may have
been driven by the smaller sample size in which a higher
proportion of respondents reported a higher frequency of
NSNHEs than did respondents in other countries. Furthermore,
one person in Italy who reported a health care visit due to a fall
also reported a daily frequency of NSNHEs. This high frequency
and related costs may represent a unique case.
Several limitations with this study should be mentioned. First,
the response rate for the survey was 78.9% and although this can
be considered a very high response rate, it is feasible that some
response bias may have been introduced because of nonrespond-
ers. Because of ethical considerations, no information was col-
lected on nonresponders because they did not sign an informed
consent form. Therefore, comparison of responders and non-
responders for characteristics that may have introduced non-
responder bias was not possible. Furthermore, accuracy of
reporting, as with any survey, is a consideration because recall
bias may have inﬂuenced ﬁndings. Recall of episodes of NSHEs,
however, up to a week can be considered relatively accurate [40],
and recall of longer durations was considered to be accurate as
reported by focus group participants in the groups conducted to
generate items for this survey. The recall period for most of the
sample (76.3%) was within the last 2 weeks, and no recall
period was longer than 1 month. Given the self-report nature of
this data, some respondents may have overestimated or under-
estimated variables such as income or age or misrepresented
their diagnosis. This bias should be recognized as a potential
bias in all studies using self-reported data. The minimal
honoraria for completing the survey, as well as the fact that
respondents recruited via panels were already preidentiﬁed on
some of the variables that may have been misrepresented (e.g.,
age and income), however, may have reduced the risk of this
potential bias. Also, as in all research, there may be a potential
bias of collecting data only from persons who choose to
participate in research. The fact that this study collected data
via an Internet-based survey may also introduce a selection
bias in the respondents who were able to participate (i.e., only
literate respondents with access to a computer). The propor-
tion of Internet users in all nine countries based on total
population (including infants and the very old), however, is
high (highest in Sweden, 92%, to lowest in Italy, 47.7%). We
suspect that Internet usage is higher for the predominant age
group relevant in this study (18–64 years). Moreover, the rate ofliteracy is high in all nine countries (99% in most countries,
with lowest in Spain, 97.7%) [13]. Accuracy may be impacted by
any incentives given to the respondents for completion of the
survey. In this study, the amount of the incentive was minimal
(US $3–$5 depending on country), which we believe would not
have affected responses or decisions to participate in the study.
Furthermore, all countries that participated in the study were
North American or Western European countries where the
similarities in diabetes care can be considered to outweigh
the differences. It is unclear whether in countries with more
distinct medical systems, cultures, or diabetes management
pathways, a similar study would yield the same results. Last,
given the panel nature of the survey, it was not possible to have
a physician-conﬁrmed diagnosis. It was not known, however,
to the patients who completed the screener beforehand that
only those with diabetes would be administered the survey. In
the screener, the subjects were provided with several medical
conditions and asked to check which they had been diagnosed
with by a physician. Only those who checked diabetes, among
the multiple possibilities, were invited to complete the full
survey. It is possible that some patients did misrepresent their
diagnosis; however, given the small honorarium incentive
provided and the a priori known panel screening character-
istics, we believe that this group was not large enough to
inﬂuence ﬁndings.Conclusions
In conclusion, this study strongly suggests that NSNHEs are
signiﬁcant events for patients and represent an important eco-
nomic burden in terms of both lost work productivity and
increased health care resource utilization across several coun-
tries. These events should not be considered “minor” or “non-
severe,” and incorporating a discussion of these events and
optimal corrective action strategies into all diabetes management
treatment plans should facilitate reducing the economic burden
of NSNHEs.
Source of ﬁnancial support: This study was funded by Novo
Nordisk A/S.
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